Cite
HARVARD Citation
Peters, S. et al. (2023). A UK Real-world Evaluation of Efficacy and Toxicity of Second-line Trastuzumab Emtansine and Third-line Trastuzumab Deruxtecan in HER2-positive Advanced Breast Cancer. Clinical oncology. 35 (6), pp. e419-. [Online].